glp-1 compounding pharmacy Compounded No platform charges Photo by 1st Order Compounding

Postpartum dietary, sleep, and physical activity behaviors: A qualitative study to inform efforts to address postpartum weight retention

Research shows that taking GLP-1 receptor agonists may increase a persons risk of developing certain vision problems, including NAION, which can cause sudden, painless vision loss in one eye due to reduced blood flow in the optic nerve

This action makes these agents a therapeutic option for weight loss.56 Although to a lesser extent, delay in gastric emptying contributes to the anorexigenic effect.61 Clinical trials conducted with GLP-1 receptor agonists in patients with obesity (or excess weight [BMI 27] with comorbidities), or with DT2 and excess weight or obesity, have achieved weight reductions greater than those reported for orlistat, as well as those observed with oral antidiabetic agents such as the sodium glucose type 2 cotransporter inhibitors (SGLT2i) or metformin.62 In a meta-analysis of more than 10 000 patients with obesity, those treated with GLP-1 receptor agonists lost, on average, 7kg more than those in the control group.63 Weight loss of up to 15% has been observed after 12 months of treatment,64,65 a level that had only been achieved through surgical methods

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, et al

Zaccardi F, Htike ZZ, Webb DR, Khunti K, Davies MJ

Furthermore, compared to dulaglutide, tirzepatide at a dose of 0.75 mg once weekly was more effective at controlling blood glucose levels in this cohort